Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New injection shows promise for untreatable liver cancer

NCT ID NCT06310590

First seen Feb 03, 2026 · Last updated May 20, 2026 · Updated 16 times

Summary

This early-stage study tested a new drug called NRT6003 in 40 adults with liver cancer that cannot be surgically removed. The main goals were to check safety and see if the injection shrinks liver tumors. Researchers measured side effects and how long the tumors stayed under control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Hunan Provincial People's Hospital

    Changsha, Hunan, China

  • The Affiliated Hospital of Southwest Medical University

    Luzhou, Sichuan, China

  • The First Affiliated Hospital of Jinan University

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, 310022, China

  • Zhongda Hospital, Southeast University

    Nanjing, Jiangsu, 210009, China

  • Zhongshan Hospital, Fudan University

    Shanghai, China

Conditions

Explore the condition pages connected to this study.